Navigation Links
NOTES research activities increase with grants from Olympus medical Systems totaling $1 million
Date:7/9/2008

OAK BROOK, Ill., July 10, 2008 The Natural Orifice Surgery Consortium for Assessment and Research™ (NOSCAR™), a joint effort of the American Society for Gastrointestinal Endoscopy (ASGE) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), today announced Olympus' continuing commitment to funding research in an emerging transdisciplinary therapy known as Natural Orifice Translumenal Endoscopic Surgery™ (NOTES™), with a $500,000 grant to the existing Olympus Research Fund supporting NOTES™ research. The grant increases Olympus' total funding to $1 million. NOTES™, which is performed by using the patient's natural openings for surgery, will be discussed among researchers from July 10-12, 2008 at the 3rd International Conference on NOTES™ in San Francisco, Calif.

"The Olympus Research Fund established in 2007 has already supported nine studies producing results that are advancing the understanding and applications of this fascinating and innovative technique," said Haruhito Morishima, president, Olympus Medical Systems Corporation. "As the world's leader in endoscopy, we are proud to continue our support of NOTES™ research, an approach that could ultimately represent a major paradigm shift in minimally invasive therapy."

This fund was established with an initial $500,000 grant from Olympus. Though studies from this grant are ongoing, one of the nine studies that has been completed is expected to be published in two peer-reviewed journals. Researchers will learn more about these studies at the upcoming NOTES™ conference.

"NOTES™ is moving forward more rapidly than initially expected," said Robert H. Hawes, MD, FASGE, ASGE past president and NOSCAR™ Joint Committee co-chair. "Three years ago, we never anticipated the progress in the research arena that has been made in such a short period. Thanks to leaders such as Olympus, we are making great str
'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
3. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
4. Flextronics Announces Redemption and Change of Control Repurchase Offer for Solectron 8.00% Senior Subordinated Notes and Planned Change of Control Repurchase Offer for Solectrons 0.50% Senior Convertible Notes
5. Flextronics Announces Change in Control Repurchase Offer for Solectrons 0.50% Senior Convertible Notes
6. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
7. Providence Service Corporation Completes Private Placement of $70 Million of Convertible Senior Subordinated Notes
8. MediNotes EMR Now Interfaces With 76 Practice Management Systems, Allowing More Medical Practices to Replace Their Patients Aging Paper Medical Records
9. AllerNotes Help Take Food Allergies Off the Table
10. MQ Associates, Inc. Announces Expiration of its Tender Offers for its 12 1/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Medquest, Inc.s 11 7/8% Senior Subordinated Notes Due 2012 (CUSIP No. 58505DAD1)
11. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Senokot 28R 29 Tablets Undergo a Natural Makeover 53857 1Senokot 28R 29 Tablets Undergo a Natural Makeover 53857 2Decision Resources Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals Fostamatinib Disodium 53855 1Decision Resources Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals Fostamatinib Disodium 53855 2West Virginia Public Employees Insurance Agency Awards Overpayment Project to HMS 53853 1West Virginia Public Employees Insurance Agency Awards Overpayment Project to HMS 53853 2
Other Medicine Technology:New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 2New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 3New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 4New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 5New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C) 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8